The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab

OBJECTIVES: To assess whether treatment with one of three novel biological DMARDs; rituximab, abatacept or tocilizumab reduce cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis (RA). METHODS: This is an open, observational and prospective study with visits at baseline, 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Provan, Sella Aarrestad, Berg, Inger Jorid, Hammer, Hilde Berner, Mathiessen, Alexander, Kvien, Tore Kristian, Semb, Anne Grete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482693/
https://www.ncbi.nlm.nih.gov/pubmed/26114946
http://dx.doi.org/10.1371/journal.pone.0130709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482693/
https://www.ncbi.nlm.nih.gov/pubmed/26114946
http://dx.doi.org/10.1371/journal.pone.0130709

Ejemplares similares